Clinical Cancer Research · 2011 · 343 citations · 34 references
MedicineCancer BiologyOncologyInflammationMetastasisTumor MicroenvironmentCancer Stem Cell BiologyCancer Stem Cell NicheCancer Stem CellsCytokine BiologyCytokine SignalingInflammatory SignalingCancer Stem Cell Signaling PathwaysCytokine Network InteractionsCytokine Signaling In CancerCytokine Signaling In TumorsCytokine Signaling NetworksInflammatory Cytokine ProductionTumor Microenvironment RegulationTumor-associated Cytokines
Many human cancers are driven by a subpopulation of cancer stem cells that contribute to metastasis and treatment resistance, and these cells are regulated by inflammatory cytokine networks in the tumor microenvironment, resembling chronic inflammation pathways. The study proposes that blocking tumor‑microenvironment cytokine signals with anti‑inflammatory agents could target CSCs, and future trials are needed to assess clinical benefit. These interactions involve IL‑1, IL‑6, and IL‑8 activating Stat3/NF‑κB pathways, creating positive feedback loops that drive CSC self‑renewal. Published in Clin Cancer Res 17(19):6125–9; ©2011 AACR.
Abstract There is substantial evidence that many human cancers are driven by a subpopulation of cells that display stem cell properties. These cancer stem cells (CSC) may also contribute to metastasis and treatment resistance. Furthermore, just as normal stem cells are regulated by their microenvironment, or niche, CSCs interact with and in turn are regulated by cells in the tumor microenvironment. These interactions involve inflammatory cytokines, such as interleukin (IL)-1, IL-6, and IL-8, which in turn activate Stat3/NF-κB pathways in both tumor and stromal cells. Activation of these pathways stimulates further cytokine production, generating positive feedback loops that in turn drive CSC self-renewal. These cytokine loops and the pathways they regulate resemble those activated during chronic inflammation and wound healing, and may contribute to the known link between inflammation and cancer. Inhibitors of these cytokines and their receptors have been developed as anti-inflammatory agents. By blocking signals from the tumor microenvironment, these agents have the potential to target CSCs. Future clinical trials using these compounds will be needed to determine whether targeting the CSC population has clinical benefit. Clin Cancer Res; 17(19); 6125–9. ©2011 AACR.
34
Prospective identification of tumorigenic breast cancer cells
Muhammad Al‐Hajj, Max S. Wicha, Adalberto Benito‐Hernández et al. · Proceedings of the National Academy of Sciences · 2003 · 10.4K citations · Full text
Medicine, Cell Biology, Oncology +11
Identification and expansion of human colon-cancer-initiating cells
Lucia Ricci‐Vitiani, Dario Lombardi, Emanuela Pilozzi et al. · Nature · 2006 · 4K citations
Medicine, Cancer Biology, Oncology +12
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Antoine E. Karnoub, Ajeeta B. Dash, Annie P. Vo et al. · Nature · 2007 · 3.2K citations
Medicine, Cell Biology, Oncology +12
A Perivascular Niche for Brain Tumor Stem Cells
Christopher Calabrese, Helen Poppleton, Mehmet Koçak et al. · Cancer Cell · 2007 · 2.2K citations · Full text